Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

NCT00543439 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

BIOLOGICAL: Moroctocog alfa (AF-CC)
BIOLOGICAL: Moroctocog alfa (AF-CC)

Sponsor

Pfizer